EC1169 PSMA-tubulysin (Prostate cancer)

Delivers A Potent Cytotoxic Agent To Cancer Cells That Express Prostate-Specific Membrane Antigen (PSMA)

EC1169 is an investigational, proprietary, injectable, PSMA-targeted SMDC consisting of a potent cytotoxic agent, tubulysin B hydrazide (TubBH). TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. EC1169 is being co-developed with EC0652 as its companion imaging agent.

Development Stage

EC1169 is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer.